Brought to you by 
GE and Eli Lilly partner to develop Alzheimer's diagnostics
09 May 2005
Executive Summary
General Electric's GE Healthcare and GE Global Research divisions have entered into an agreement with Eli Lilly & Co. to simultaneously discover and develop new diagnostics and treatments for early-stage Alzheimer's disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GE and Eli Lilly partner to develop Alzheimer's diagnostics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice